Navigation Links
Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
Date:5/4/2009

ATLANTA, May 4 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that positive interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien(TM) (fluocinolone acetonide (FA) intravitreal insert) will be presented today at 2:00 p.m. at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Ft. Lauderdale, FL.

The data in the presentation, entitled "Pharmacokinetics and Pharmacodynamics of Iluvien(TM) (FA intravitreal insert) for DME," were derived from the FAMOUS Study Group, which in addition to measuring systemic levels of FA, also assessed anterior chamber levels of FA, and assessed correlations between these levels and clinical outcomes.

A total of 37 subjects with DME were randomized, 20 patients on the low dose of Iluvien and 17 patients on the high dose of Iluvien. Results showed an improvement in best corrected visual acuity associated with a reduction in center subfield thickness in a substantial number of patients for both doses, as well as no evidence of elevated intraocular pressure in the low dose.

"Alimera is excited to share more details of this study," said Dan Myers, CEO, Alimera Sciences. "We believe these results continue to be in line with our expectations regarding the safety and efficacy of Iluvien."

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which Alimera is studying as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera has exercised its option to acquire a license with respect to one of these classes of NADPH oxidase inhibitors.


'/>"/>
SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
2. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
5. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... NEW YORK , January 24, 2017 ... of the fastest growing industries in the United ... for medicinal use in 2016. In addition, Proposition 64, the ... 57.13% for and 42.87% against on November 8, 2016. This ... are allowed to use and to grow a certain amount ...
(Date:1/24/2017)... , January 24, 2017 ... value of USD 3.8 billion by 2025, according to ... market growth can be attributed to the rising initiatives ... early diagnosis of micro calcifications in breast tissue. Some ... CDC, and Breast Cancer Organization are promoting the early ...
(Date:1/24/2017)... -- Aptuit, LLC, hat heute den Beginn ... General Hospital (MGH) unter Leitung von Dr. Laurence ... und Validierung neuartiger Targets in gramnegativen Bakterien.  Aptuit erhofft ... Antibiotika bei der Behandlung schwerer Infektionen entgegenwirken können. ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... The ... MSC Cruises as part of the line’s 4th Annual MSC True Partnerships’ Awards. ... performing North American travel partners for the year based on overall business growth in ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... announced that it has officially formed a distribution partnership with Byers Scientific ... industrial odor management industry. , Through the agreement, OMI Industries formulated a special ...
(Date:1/24/2017)... ... January 24, 2017 , ... Providing solutions to critical ... from the Frank Hawkins Kenan Institute of Private Enterprise at the ... policy makers identified concrete solutions at the “What’s Next, America?” conference at the ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January 23, ... Kleyne, the nation’s foremost water advocate and host of the nationally syndicated The ... Voice America, once again welcomed one of her favorite guests and colleagues, Dr. ...
(Date:1/24/2017)... ... ... “Speaking With God’s Voice”: a resolute and spirited call for anointed preaching ... A. Miraglia, a born-again believer, who spent his years teaching high school and Sunday-school, ... “There is little doubt that God Himself prepared me for this study, and God’s ...
Breaking Medicine News(10 mins):